EL7.AI
StocksMedium•23 October 2026•
3 min read

Lycia Expands IPO After Initial Plan to Sell 14.7 Million Shares

Key Facts

1Preliminary data showed a maximum mean reduction of 96% in IgE after a 70 mg dose, with levels in a majority of participants remaining more than 95% lower after 28 days.
2The company expects additional data on LCA-0061 in 2027 and preliminary data on LCA-0062 in the second half of 2027, subject to regulatory approval.
3The management group and major shareholders held 71.7% of the voting power, and the registration statement expected them to retain about 52.7% after the offering.

The final offering was larger than the initial plan, according to the pricing statement cited in the company’s filing. The company intends to use the net proceeds, together with its cash and marketable investments, to fund its clinical programs, research and development, working capital and general corporate purposes. Priorities include advancing its portfolio targeting immunoglobulin E, or IgE, and its Graves’ disease treatment program.

Lycia is a clinical-stage biotechnology company developing therapies designed to degrade extracellular disease-related proteins, with an initial focus on immunology, inflammation and allergic diseases, according to the registration statement. This business puts the company’s future value to the test of clinical progress, as its programs remain at early stages. Its IgE portfolio includes LCA-0061 and LCA-0062, while LCA-0321 targets Graves’ disease. The company said the net proceeds from the offering, together with its cash resources and marketable investments, will support these programs and research and development. It also listed working capital and general corporate purposes among the planned uses, without allocating a separate amount to each program in the information provided here.

The company is conducting a Phase 1 human trial of LCA-0061 to study safety, tolerability and pharmacokinetics. The study includes patients with food allergies in a multiple-dose cohort. Preliminary data reported in the registration statement showed that a group receiving a single 70 mg subcutaneous dose had a maximum mean reduction of 96% in IgE levels from baseline. Levels in a majority of participants remained more than 95% below baseline 28 days after the dose, according to the filing. These figures describe preliminary results for the specified group, dose and period, while the trial is designed to assess safety, tolerability and pharmacokinetics. The company therefore links the program’s progress to additional clinical data, not simply to the amount of financing it raised.

For its Graves’ disease program, Lycia said it is conducting a Phase 1 trial of LCA-0321 in patients with the disease. LCA-0062 remains in investigational new drug application-enabling activities, a stage that precedes the start of clinical trials, according to the registration statement. The company expects additional data on LCA-0061 in 2027, including participants with elevated IgE and patients with food allergies. It also expects preliminary data on LCA-0062 in the second half of 2027, if the program receives regulatory approval. These timelines put the portfolio on a sequence of milestones, with each candidate at a different stage.

The registration statement also carries a warning about the company’s financial position: Lycia said it has incurred net losses since its inception and expects them to continue for the foreseeable future. It added that the need for additional financing could affect its ability to continue its development plans. The offering comes in this context, to fund clinical development and research and development, as well as working capital and general corporate purposes. Before the offering, a group of executive officers, directors and major shareholders held 71.7% of the voting power as of September 30, 2026. The registration statement expected the group to retain about 52.7% of the voting power after the offering, based on its assumptions.